Lyra Therapeutics, Inc. (LYRA)
Stock Price:
$11.11 USD
-0.15 (-1.33%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
143.59M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
12.92M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$11.11 |
| Previous Close |
$11.26 |
| Change ($) |
-0.15 |
| Change (%) |
-1.33% |
| Day's Open |
11.33 |
| Day's Range |
10.83 - 11.46 |
| Day's Volume |
74,526 |
| 52-Week Range |
10.60 - 22.00 |
More Stats
| Market Cap |
143.59M |
| Enterprise Value |
111.13M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.92M |
| Float |
4.90M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
132,364 |
| Short Ratio |
0.91 |
| Short % of Float |
2.34% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
27.60 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
32.47M |
| Net Cash / Share |
2.51 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-51.21% |
| ROE |
-106.55% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$24.33*
(118.99% upside)
Low
21.0
Current: 11.11
High
28.0
Target: 24.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 1.24 |
| Gross Profit | - | 1.24 |
| Operating Income | -16.52 | -7.26 |
| Net Income | -16.31 | -6.03 |
| Shares Outstanding | 0.20 | 0.17 |
| Earnings Per Share | -82.23 | -36.79 |
| Operating Cash Flow | -13.75 | -6.64 |
| Capital Expenditures | -0.21 | -0.04 |
| Free Cash Flow | -13.97 | -6.68 |
| Cash & Equivalents | 10.14 | 24.22 |
| Total Debt | 3.33 | - |
| Net Cash / Debt | 6.81 | 24.22 |
| Assets | 14.96 | 25.36 |
| Liabilities | 7.64 | 2.08 |
| Book Value | -123 | -107 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Lyra Therapeutics, Inc. |
| Country |
United States |
| Employees |
34 |
| CEO |
Maria Palasis |
Stock Information
| Ticker Symbol |
LYRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LYRA |
| IPO Date |
May 1, 2020 |
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.